Adenovirus-mediated Gene Transfer Into Infarcted Myocardium: Feasibility, Timing, and Location of Expression

doi:10.1006/jmcc.1996.0199

Journal of Molecular and Cellular Cardiology

Volume 28, Issue 10, October 1996, Pages 2057-2067

https://doi.org/10.1006/jmcc.1996.0199 Get rights and content

Abstract

Gene transfer as a therapeutic modality for the treatment of myocardial ischemia and/or infarction has been proposed as a revolutionary approach to improve collateral circulation, enhance myocardial viability and amplify healing. Our study was undertaken to assess the feasibility, efficiency, anatomic distribution, timing and localization of adenovirus-mediated gene transfer into the vicinity of infarcted myocardium in the adult mammalian heart. We induced myocardial infarction by subjecting rats to 60 min of coronary artery occlusion followed by sustained reperfusion. Gene transfer into the infarction area was performed using direct injection of a replication-defective adenovirus vector encoding the bacterial reporter gene,β-galactosidase. A total of 5.0×10⁹plaque-forming units of virus was delivered into the left ventricular myocardium either immediately (n=7) or at 7 (n=6), 22 (n=5) or 30 days (n=5) after reperfusion of rat hearts. Control rats received either 50μl of saline 13 days after myocardial infarction (n=2) or were not subjected to infarction and received Adenovirus carrying theβ-galactosidase gene as described above (n=4). All rats were killed at 7 days after cardiac injection. Hearts were harvested, frozen and sectioned and stained forβ-galactosidase activity and with hematoxylin and eosin. Sections were evaluated by light microscopy. Relativeβ-galactosidase activity was measured by digital planimetry and expressed as the ratio of the maximal area ofβ-galactosidase staining relative to the total area of the section examined (%±S.E.M.).β-galactosidase gene expression was limited mainly to viable myocytes at the border of the myocardial infarction. The area of transgene expression in the non-infarcted hearts (28±7%) was significantly higher (P=0.02) than at any time point studied in infarcted tissues (3.4±1.2%, 1.4±1.0%, 2.8±0.8% and 3.4±0.9% at reperfusion and at 7, 22 and 30 days after myocardial infarction, respectively). Hearts injected 7 days after infarction had significantly less transgene activity (P=0.03) with three of five samples displaying no macroscopically visibleβ-gal activity. Following viral injection, an inflammatory response consisting of mononuclear cell infiltration was much less intense seven days following injection in non-infarcted control rat hearts than at any of the time points examined for infarcted hearts. Gene transfer into infarcted myocardium, while feasible, was limited by low transfection efficiency when compared to non-infarcted normal myocardium. Transgene expression in the infarcted myocardium appears restricted to residual cardiomyocytes in the periphery. Nevertheless, the ability to introduce genes into these viable peripheral cells might be a useful therapeutic strategy for enhancing neovascularization, collateral flow and healing.

References (0)

Cited by (47)

In vivo reprogramming for heart regeneration: A glance at efficiency, environmental impacts, challenges and future directions
2017, Journal of Molecular and Cellular Cardiology
Citation Excerpt :
This suggests that immune responses contribute to the loss of viral-infected cells in immunocompetent animals. Additionally, intense inflammatory reactions were reported due to injection of a high dose of adenovirus in injured rat heart [26,90,91]. Therefore, immune system response to viral vectors is a substantial complication for induction of reprogramming in human tissues.
Replacing dying or diseased cells of a tissue with new ones that are converted from patient's own cells is an attractive strategy in regenerative medicine. In vivo reprogramming is a novel strategy that can circumvent the hurdles of autologous/allogeneic cell injection therapies. Interestingly, studies have demonstrated that direct injection of cardiac transcription factors or specific miRNAs into the infarct border zone of murine hearts following myocardial infarction converts resident cardiac fibroblasts into functional cardiomyocytes. Moreover, in vivo cardiac reprogramming not only drives cardiac tissue regeneration, but also improves cardiac function and survival rate after myocardial infarction. Thanks to the influence of cardiac microenvironment and the same developmental origin, cardiac fibroblasts seem to be more amenable to reprogramming toward cardiomyocyte fate than other cell sources (e.g. skin fibroblasts). Thus, reprogramming of cardiac fibroblasts to functional induced cardiomyocytes in the cardiac environment holds great promises for induced regeneration and potential clinical purposes. Application of small molecules in future studies may represent a major advancement in this arena and pharmacological reprogramming would convey reprogramming technology to the translational medicine paradigm. This study reviews accomplishments in the field of in vitro and in vivo mouse cardiac reprogramming and then deals with strategies for the enhancement of the efficiency and quality of the process. Furthermore, it discusses challenges ahead and provides suggestions for future research. Human cardiac reprogramming is also addressed as a foundation for possible application of in vivo cardiac reprogramming for human heart regeneration in the future.
Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Heart Failure
2008, Journal of Cardiac Failure
Citation Excerpt :
The buffer without vector serves as the matching placebo. Many surgical and catheter-based systems have been used with various degrees of success to induce viral based gene transfer in large animals and in humans.28–32 We have conducted a number of studies with AAV1/SERCA2a that have compared efficacy and cardiac delivery using various catheter-based delivery systems or devices.
Heart failure (HF) remains a major cause of morbidity and mortality in North America. With an aging population and an unmet clinical need by current pharmacologic and device-related therapeutic strategies, novel treatment options for HF are being explored. One such promising strategy is gene therapy to target underlying molecular anomalies in the dysfunctional cardiomyocyte. Prior animal and human studies have documented decreased expression of SERCA2a, a major cardiac calcium cycling protein, as a major defect found in HF.
We hypothesize that increasing the activity of SERCA2a in patients with moderate to severe HF will improve their cardiac function, disease status, and quality of life. Gene transfer of SERCA2a will be performed via an adeno-associated viral (AAV) vector, derived from a nonpathogenic virus with long-term transgene expression as well as a clinically established favorable safety profile.
We describe the design of a phase 1 clinical trial of antegrade epicardial coronary artery infusion (AECAI) administration of AAVI/SERCA2a (MYDICAR) to subjects with HF divided into 2 stages: in Stage 1, subjects will be assigned open-label MYDICAR in one of up to 4 sequential dose escalation cohorts; in Stage 2, subjects will be randomized in parallel to 2 or 3 doses of MYDICAR or placebo in a double-blinded manner.
Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction
2003, Molecular Therapy
Citation Excerpt :
Adenoviral gene delivery is the most powerful method of cardiac gene therapy [26]. Before the therapeutic experiments, we confirmed the expression of the adenoviral gene in the border area between the viable and the infarcted heart tissue, because it was previously reported that gene expression level after adenoviral transfer of gene was reduced in the area of infarction to 10–20% of that in the normal heart [24]. Through a series of experiments, we were able to obtain a level of expression of the transferred gene that we considered adequate for therapeutic use.
In acute myocardial infarction (AMI), prognosis and mortality rate are closely related to the infarct size and the progression of postinfarction cardiac failure. Angiogenic gene therapy has presented a new approach for the treatment of AMI. Angiopoietin-1 (Ang1) is a critical angiogenic factor for vascular maturation and enhances vascular endothelial growth factor (VEGF)-induced angiogenesis in a complementary manner. We hypothesized that gene therapy using Ang1 for AMI might promote angiogenesis cooperatively with intrinsic VEGF, since high concentrations of circulating VEGF have been reported in AMI. To evaluate our hypothesis, we employed a rat AMI model and adenoviral Ang1 (HGMW-approved gene symbol ANGPT1) gene transfer to the heart. A significant increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts with adenoviral Ang1 gene treatment compared with control infarcted hearts treated with saline or adenoviral vector containing the β-galactosidase gene. Furthermore, the Ang1 group showed significantly higher cardiac performance in echocardiography (55.0% of ejection fraction, P < 0.05 vs control) than the saline or adenoviral controls (36.0 or 40.5%, respectively) 4 weeks after myocardial infarction. The adenoviral delivery of Ang1 during the acute phase of myocardial infarction would be feasible to attenuate the progression of cardiac dysfunction in the rat model.
Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic acid by ultrasound-targeted microbubble destruction
2003, Journal of the American College of Cardiology
This study was undertaken to optimize echocardiographic parameters for successful gene delivery to the heart and to extend the method from adenoviral to plasmid deoxyribonucleic acid (DNA).
We have previously shown that ultrasound-targeted microbubble destruction can direct tissue expression of adenoviral transgenes to the heart. The optimal echocardiographic parameters for this technique have not been reported.
Adenoviral or plasmid DNA encoding the luciferase reporter gene was incorporated into liposome microbubbles and infused intravenously into anesthetized rats. We systematically evaluated the effects of ultrasound parameters known to influence microbubble destruction, including electrocardiogram (ECG) triggering, ultrasound frequency, mode of ultrasound, and mechanical index, on gene expression in rat myocardium four days after treatment. In addition, gene expression in heart, liver, and skeletal muscle were compared between adenoviral and plasmid DNA.
Optimal ultrasound parameters for this technique include low-transmission frequency (1.3 MHz), maximal mechanical index, and ECG triggering to allow complete filling of the myocardial capillary bed by microbubbles. No difference was seen between ultraharmonics and power Doppler mode. Using adenoviral DNA, optimal ultrasound parameters yielded myocardial luciferase activity on the order of 10⁴relative light units/mg protein/min but with even higher liver activity. Plasmid DNA was expressed in rat myocardium at similar levels but without detectable liver expression.
Ultrasound-targeted microbubble destruction can be used to deliver adenoviral or plasmid DNA to the myocardium. This technique holds great promise in applying the rapidly expanding repertoire of gene therapies being developed for cardiac disease.
Hypoxic preconditioning triggers myocardial angiogenesis: A novel approach to enhance contractile functional reserve in rat with myocardial infarction
2002, Journal of Molecular and Cellular Cardiology
A modern experimental strategy for treating myocardial ischemia is to induce neovascularization of the heart by the use of “angiogens”, mediators that induce the formation of blood vessels, or angiogenesis. Studies demonstrated that coronary collateral vessels protect ischemic myocardium after coronary obstruction; therefore we sought to examine a novel method of stimulating myocardial angiogenesis through hypoxic preconditioning at both capillary (using anti-CD31) and arteriolar (using anti- α smooth muscle actin) levels and also investigate whether such treatments could preserve left ventricular contractile functional reserve and regional blood flow by increasing vascular endothelial growth factor (VEGF). Male Sprague-Dawley rats were randomly divided into four groups: normoxia+sham surgery (CS), normoxia+permanent left anterior descending coronary artery (LAD) occlusion (CMI), hypoxic preconditioning+sham surgery (HS) and hypoxic preconditioning+permanent LAD occlusion (HMI). Rats in the preconditioned groups were subjected to systemic hypoxemic hypoxic exposure (10±0.4% O₂) for 4 h followed by a 24 h period of normoxic reoxygenation prior to undergoing LAD occlusion. Rats in the normoxia group were time matched with the preconditioned group and maintained under normoxic conditions for a 28 h period prior to LAD occlusion. Western blot analysis was performed to measure VEGF expression and TUNEL staining with endothelial cell-specific antibody, anti-VWF, was used to examine endothelial apoptosis. One, two and three weeks after the LAD occlusion, baseline left ventricular pressures were monitored and recorded. Pharmacological stress tests with dobutamine infusion in progressively increasing doses revealed significantly elevated contractile reserve at each dose point in the HMI group compared to the CMI group. The HMI group displayed statistically significant increases in capillary as well as arteriolar density after 1, 2 and 3 weeks post-operation. Blood flow was also significantly elevated in the HMI groups when compared to the CMI group. The extent of endothelial cell apoptosis was found to be inversely proportional to VEGF expression. It was concluded that hypoxic preconditioning stimulates myocardial angiogenesis to an extent sufficient to exert significant cardioprotection in a rat model of myocardial infarction progressing to heart failure as evidenced by increased capillary/arteriolar density and enhanced ventricular contractile functional reserve.
A survival model for the study of myocardial angiogenesis
2002, Methods in Enzymology
The chapter presents a study on myocardial angiogenesis. Angiogenesis is known to be the body's natural healing process in which new blood vessels grow in response to injury. In the myocardium, hypoxia usually occurs during ischemic episodes. Such ischemic hypoxia is often followed by reperfusion. It is during this subsequent reperfusion period that reoxygenation occurs and reactive oxygen intermediates are formed. For the study of angiogenesis in the infarcted myocardium, a rat survival model of chronic myocardial infarction surgery is developed, and the examination of the left ventricular response during pharmacological stress, testing with dobutamine as a measure of cardiac reserve is conducted. The experimental protocol described in the chapter demonstrates myocardial angiogenesis stimulated by nonlethal moderate hypoxic challenge by utilizing an animal model of chronic myocardial infarction progressing to heart failure. Such angiogenic effects of preconditioning were found to be dim to its ability to augment vascular endothelial growth factor (VEGF), protein expression, which presumably played a crucial role in reducing endothelial cell apoptosis, a proved determinant for congestive heart failure.

View all citing articles on Scopus

^f1: The first two authors contributed equally on the preparation of this manuscript.

^f2: Please address all correspondence to: R. A. Kloner, The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017, USA.

View full text

FeatureAdenovirus-mediated Gene Transfer Into Infarcted Myocardium: Feasibility, Timing, and Location of Expression

Abstract

Feature
Adenovirus-mediated Gene Transfer Into Infarcted Myocardium: Feasibility, Timing, and Location of Expression